Florida Cancer Specialists

What Florida Cancer Specialists does

Florida Cancer Specialists & Research Institute (FCS) is a private, physician-owned community oncology practice headquartered in Fort Myers, Florida, founded in 1984. It operates one of the largest community-based hematology and oncology footprints in the United States, with more than 250 physicians across nearly 100 clinic locations statewide and an employee base of 1,001-5,000. Its core product is comprehensive cancer care across all major disease sites — chemotherapy, immunotherapy, targeted therapy, bispecific antibody therapy, radiopharmaceutical therapy, radiation, CAR T-cell therapy, and supportive services — augmented by an in-house specialty pharmacy (Rx To Go, ACHC-, URAC-, and NABP-accredited), in-house genomic and germline testing, on-site pathology, PET/CT imaging, behavioral health, telehealth, and value-based-care programs.

FCS monetizes cancer care through standard payer billing (Medicare, Medicaid, and commercial insurance) for patient services, sponsored clinical trial participation (with biopharma partners including AstraZeneca, Daiichi Sankyo, and Johnson & Johnson via Sarah Cannon Research Institute), pharmacy dispensing through Rx To Go, and value-based contracts led by SVP Kiana Mehring. Its research engine is anchored by three Drug Development Units for early-phase trials (Sarasota, Lake Mary, plus a third site) and Disease Site Committees for late-phase work; the practice sustains 180+ active clinical trials and 600+ annual enrollments across 29 trial-active clinics, more than any other private oncology practice in Florida. Key strategic partners include Sarah Cannon Research Institute (research), McKesson/Ontada (real-world data), Orlando Health (co-located cancer center), the U.S. Department of Veterans Affairs (TeleOncology), and the Florida Cancer Innovation Fund.Leadership comprises CEO Ryan Ciarrocchi (with Nathan H. Walcker also referenced), CFO Charles Webb, President and Managing Physician Dr. Lucio N. Gordan, VP of Informatics Trevor Heritage, plus medical directors for drug development (Dr. Manish Patel), late-phase research (Dr. Bradley Monk), cell therapy (Dr. Shachar Peles), and research/clinical trials (Dr. Gustavo A. Fonseca). FCS is regulated through multiple national accreditations, including ACHC accreditation with distinction in oncology, and earned the ASCO Clinical Trials Participation Award. The company is not PE-backed, has no public listing, and reports revenue only through private channels; expansion is organic, driven by clinic densification in Florida, partnership-driven trial access, and adjacent research and pharmacy integration.

Name

Florida Cancer Specialists

Legal name

Florida Cancer Specialists & Research Institute

Website

https://flcancer.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Community Oncology and Hematology Care Services

NAICS

Offices of Physicians (62111), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Pharmaceutical Preparations (2834)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Oncology & Cancer Specialty Hospitals (HLAFAHAC), Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Community oncology care
• Hematology medical oncology
• Clinical trials research
• Specialty pharmacy services
• Precision cancer treatment

Headquarters

HQ city

Fort Myers

HQ country

United States

HQ region

North America

Offices16 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain, Others

Revenue model

1. Patient Care Services: FCS generates revenue through billable oncology and hematology care services including chemotherapy, immunotherapy, targeted therapies, radiation treatment, diagnostic imaging, laboratory services, and clinical consultations billed to Medicare, Medicaid, and commercial payers.
2. Clinical Trial Participation: Revenue from conducting clinical trials in partnership with pharmaceutical companies and research organizations such as Sarah Cannon Research Institute, with trials sponsored by pharmaceutical companies including AstraZeneca, Daiichi Sankyo, and Johnson & Johnson.
3. In-House Specialty Pharmacy (Rx To Go): FCS operates Rx To Go, an in-house specialty pharmacy delivering oral oncolytic therapies, generating pharmacy dispensing revenue and enabling integrated patient care.
4. Value-Based Care Contracts: FCS participates in value-based oncology care arrangements with payers, including AI-powered contracting strategies and population health management programs led by SVP Kiana Mehring.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Core offering

Florida Cancer Specialists & Research Institute is a community-based hematology and oncology practice delivering comprehensive cancer treatment — including chemotherapy, immunotherapy, targeted therapy, bispecific therapy, radiopharmaceutical therapy, and CAR T-cell therapy — through nearly 100 clinic locations across Florida. The practice augments direct care with an integrated specialty pharmacy (Rx To Go), genomic and germline testing, on-site pathology and PET/CT imaging, telehealth services, behavioral health support, and access to more than 180 active oncology clinical trials via three Drug Development Units.

Product overview

Florida Cancer Specialists & Research Institute operates as a statewide community oncology practice offering a comprehensive cancer care ecosystem. The core offering is cancer treatment services (chemotherapy, immunotherapy, targeted therapies, radiation, bispecific therapy) delivered through 29 clinic locations across Florida. The practice augments treatment with an integrated portfolio: an in-house specialty pharmacy (Rx To Go), genetic/genomic testing, pathology, radiology imaging, telehealth services, and behavioral health support. A distinguishing feature is its clinical trials program providing access to over 180 active trials through three drug development units, enabling patients to access emerging treatments. Support services include nutrition counseling, financial navigation, support groups, and foundation grants. The organization also participates in value-based care arrangements with payers.

Differentiator

Problem solved

Functional benefit

Brands

• Rx To Go: In-house specialty pharmacy delivering oral oncolytic therapies and personalized pharmacy services to patients across Florida
• Carespace
• Ontada Health

Products and services

• Cancer Treatment Services Comprehensive hematology and oncology care including chemotherapy, immunotherapy, targeted therapies, bispecific therapy, radiopharmaceutical therapy, CAR T-cell therapy, and radiation treatment delivered across nearly 100 Florida clinic locations for adult patients with solid tumors and blood cancers.
• Clinical Trials Program Access to more than 180 active oncology and hematology clinical trials at 29 Florida clinic locations, including three Drug Development Units (DDUs) for early-phase research conducted in partnership with Sarah Cannon Research Institute, enabling patient enrollment in cutting-edge therapies before broader commercial availability.
• Rx To Go Oral Oncolytic Pharmacy In-house specialty pharmacy delivering oral oncolytic therapies and personalized pharmacy services directly to FCS patients across Florida, achieving 95% patient satisfaction and 97-98% medication adherence rates, and accredited by ACHC with distinction in oncology, URAC, and NABP.
• Telehealth Services Virtual oncology and behavioral health consultations enabling remote access to FCS cancer specialists for patients across Florida, including telehealth therapy through seven Licensed Clinical Social Workers and participation in the VA National TeleOncology Program for veterans.
• Genomic and Genetic Cancer Testing In-house germline genetic and somatic tumor genomic profiling to identify inherited cancer risks and guide personalized cancer treatment decisions through molecular profiling.
• Radiology (PET/CT) Imaging On-site diagnostic PET/CT imaging for cancer detection, staging, and treatment response monitoring at multiple FCS clinic locations across Florida.
• Pathology Services On-site pathology and hematopathology laboratory services providing cancer diagnosis, biomarker analysis, and treatment monitoring across the practice's clinic locations.
• Behavioral Health Services Behavioral health therapy, support groups, grief counseling, and mental health services delivered by seven Licensed Clinical Social Workers to cancer patients and caregivers, including telehealth and virtual Real Talk and Caregiver Support Groups.
• DigniCap Scalp Cooling FDA-cleared scalp cooling system administered during chemotherapy to reduce chemotherapy-induced hair loss for cancer patients at FCS infusion centers.
• Value-Based Oncology Care Programs Value-based oncology care contracts and population health management programs with payers, designed to improve patient outcomes and cost efficiency across community oncology care delivery.

Quantifiable outcome

• Over 600 patient enrollments in clinical trials annually
• +8 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered core.

• Paradigm HealthcoreStrategic or Co-development Partner · 1 June 2026Paradigm Health uses its SPIRE platform as technology-enabled trial infrastructure for a multicenter, hybrid, observational post-marketing study evaluating trastuzumab deruxtecan (T-DXd) in patients with HER2 IHC 3+ solid tumors. An FCS principal investigator presented the trial design at the 2026 ASCO Annual Meeting, tracking approximately 100 patients at up to 30 U.S. locations. The trial is sponsored by AstraZeneca with co-development by Daiichi Sankyo, and is part of Paradigm Health's broader FDA collaboration on real-time clinical trials.
• U.S. Department of Veterans AffairscoreStrategic or Co-development Partner · 26 May 2026FCS collaborates with the U.S. Department of Veterans Affairs to expand veteran access to advanced cancer care, offering rapid appointments within 72 hours, telehealth via the VA National TeleOncology Program, personalized treatment using molecular profiling, and a portfolio of over 180 clinical trials at 29 clinics statewide. FCS President Dr. Lucio Gordan presented these efforts at ASCO 2026, addressing veterans' 20-40% higher cancer risk.
• McKesson / OntadacoreStrategic or Co-development Partner · 24 May 2026McKesson's oncology insights business Ontada entered a data partnership with FCS to integrate the institute's cancer patient data into Ontada's real-world oncology dataset. The expanded dataset is designed to support biopharma partners, research stakeholders, and community oncology providers, reflecting McKesson's strategy to build data-driven services alongside its core distribution business.
• Community Oncology Alliance (COA)coreStrategic or Co-development Partner · 28 April 2026FCS senior leaders present at the COA 2026 Community Oncology Conference, leading sessions on cell therapy expansion, clinical trial access, AI tools, and quality metrics in oncology. FCS has over 40 years of experience and more than 180 active clinical trials.
• Research to PracticecoreStrategic or Co-development Partner · 24 April 2026FCS partnered with Research to Practice for the Fifth Annual National General Medical Oncology Summit in Orlando, Florida. The event convenes leading oncology experts to share cutting-edge data and emerging treatment strategies for personalized cancer care in community settings. FCS President Dr. Lucio N. Gordan emphasized that the program delivers actionable insights for medical oncologists and frontline cancer care professionals.
• AstraZeneca / Daiichi SankyocoreStrategic or Co-development Partner · 7 April 2026FCS participated in the PRESERVE-003 Phase 3 clinical trial evaluating gotistobart (CTLA-4 checkpoint-targeting immunotherapy) for metastatic non-small cell lung cancer. Results published in Nature Medicine showed improved effectiveness with fewer side effects compared to docetaxel. The trial advanced to a pivotal later stage.
• AstraZeneca / Daiichi Sankyo (Phase 1 KRAS G12D study)coreStrategic or Co-development Partner · 2 April 2026FCS participated in a Phase 1 clinical study for setidegrasib, a first-in-class KRAS G12D-targeted therapy, published in the New England Journal of Medicine. Results showed antitumor activity in lung and pancreatic cancers with low incidence of treatment discontinuation due to adverse events.
• Orlando HealthcoreStrategic or Co-development Partner · 23 February 2026FCS partnered with Orlando Health, which acquired Bayfront Health St. Petersburg, to staff a new cancer center at Orlando Health Institute Square. The partnership enables patients to access radiation oncology, medical oncology, surgical subspecialists, and clinical trials in a single location. The approximately 31,000-square-foot facility features 18 private exam rooms, 47 infusion chairs, on-site laboratory, and PET/CT imaging.
• Johnson & JohnsoncoreStrategic or Co-development Partner · 22 January 2026FCS is among the first in Florida to enroll patients in a Phase 3 clinical trial for pasritamig, a next-generation bispecific T-cell engager developed by Johnson & Johnson targeting castration-resistant prostate cancer. The trial involves 172 global locations evaluating survival benefits.
• Sarah Cannon Research InstitutecoreStrategic or Co-development Partner · 20 May 2024FCS partners with Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials. Over 110 new early-phase and 40 late-phase studies are launched annually through this partnership. FCS Director of Drug Development Dr. Manish Patel oversees early-phase research at three Drug Development Units in partnership with SCRI.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• The US Oncology Network: The largest national network of community-based oncology practices, supported by McKesson distribution. Directly comparable to FCS in the community oncology model, with a multi-state footprint, in-house research, and specialty pharmacy capabilities.
• OneOncology: A PE-backed national platform of community oncology practices offering clinical trials, value-based care contracting, and ancillary services. Competes head-to-head with FCS for payer contracts, physician recruiting, and biopharma trial placement.
• Tennessee Oncology: Large physician-owned community oncology practice affiliated with OneOncology, operating across Tennessee and neighboring states with a comparable mix of clinical care, clinical research, and specialty pharmacy services.
• Texas Oncology: One of the largest community-based oncology practices in the US, part of the US Oncology Network. Comparable to FCS in scale, multi-site delivery, and integration of clinical trials, imaging, and pharmacy services.
• Astera Cancer Care: A multi-state community oncology practice in the Mid-Atlantic offering medical oncology, hematology, radiation oncology, and clinical trials—comparable to FCS's integrated community-based cancer care model.
• Regional Cancer Care Associates: Physician-owned community oncology practice with locations across the Northeast US. Directly comparable to FCS in the community oncology delivery model and clinical trial access.
• New York Cancer & Blood Specialists: A multi-site community oncology and hematology practice across New York state offering chemotherapy, clinical trials, imaging, and specialty pharmacy—comparable to FCS's full-stack community oncology model.

Broad incumbents

• Mayo Clinic: Major academic medical center with significant oncology presence including the Mayo Clinic Cancer Center. Competes for complex oncology cases and clinical trial referrals in Florida through the Mayo Clinic in Jacksonville.
• City of Hope: National cancer research and treatment system (including the former Cancer Treatment Centers of America) with significant Florida presence. Competes with FCS for high-acuity oncology patients and biopharma research partnerships.

Emerging players

• Sarah Cannon Research Institute: A leading community-based clinical trial management organization and FCS's primary research partner. Highly relevant as a peer for FCS's drug development operations, though SCRI is also a customer/partner rather than a direct competitor in patient-facing care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UClVs07mD1NGe05RrbkjJ02A
• Facebookfacebook.com/FloridaCancerSpecialists
• LinkedInlinkedin.com/company/florida-cancer-specialists
• Instagraminstagram.com/floridacancerspecialists
• Xx.com/flcancerfound

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Florida Cancer Specialists